Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), announced pivotal results from the Phase III Krascendo 1 study, demonstrating that investigational next‑generation KRAS G12C inhibitor divarasib showed superior efficacy compared to current standard‑of‑care KRAS G12C inhibitors – sotorasib or adagrasib – in patients with previously treated KRAS G12C‑mutated non‑small cell lung cancer (NSCLC).
Study Snapshot
| Item | Detail |
|---|---|
| Company | Genentech, member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY) |
| Study | Pivotal Phase III Krascendo 1 |
| Asset | Divarasib – investigational, best‑in‑class, next‑generation oral KRAS G12C inhibitor |
| Comparator | Current standard of care: sotorasib or adagrasib (first‑generation KRAS G12C inhibitors) |
| Population | Previously treated KRAS G12C‑mutated NSCLC |
| Result | Statistically significant and clinically meaningful improvements in OS and PFS |
| Announcement Date | 25 October 2026 |
Drug Profile & Mechanism of Action
- Molecule: Divarasib, an investigational, best‑in‑class, next‑generation oral KRAS G12C inhibitor, discovered and developed by researchers at Roche and Genentech.
- Mechanism: Designed to selectively bind to the KRAS G12C protein, locking it in an inactive (“off”) state and thereby shutting down its tumor‑driving signaling.
- Preclinical Differentiation: Showed greater potency and selectivity compared with first‑generation KRAS G12C‑targeted therapies sotorasib and adagrasib – a profile that translated into superior efficacy in patients.
Clinical Evidence – Phase III Krascendo 1 Results
| Endpoint | Result (Divarasib) | Comparator (Sotorasib/Adagrasib) | Relative Benefit |
|---|---|---|---|
| Overall Survival (OS) | Statistically significant and clinically meaningful improvement | Standard‑of‑care KRAS G12C inhibitors | Median OS values not disclosed in the announcement |
| Progression‑Free Survival (PFS) | Significant improvement | Sotorasib or adagrasib | −42 % risk of progression or death (HR 0.58, 95 % CI 0.44–0.76, p<0.0001) |
| Objective Response Rate (ORR) | Nearly double that of comparator | Sotorasib or adagrasib | ≈ 2× ORR (absolute rates not disclosed) |
| Subgroup Consistency | OS and PFS benefit consistent across clinically relevant subgroups | – | Benefit observed regardless of PD‑L1 expression or KEAP1 mutation status |
The Krascendo 1 head‑to‑head design is notable: divarasib was compared directly against active first‑generation KRAS G12C inhibitors rather than placebo or chemotherapy, setting a high evidentiary bar that the next‑generation agent cleared across OS, PFS and ORR – with consistent benefit irrespective of PD‑L1 expression levels or KEAP1 mutation status, two factors historically associated with poorer outcomes in KRAS‑mutant NSCLC.
Market Impact & Outlook
- Standard‑of‑Care Shift: A direct head‑to‑head win over sotorasib and adagrasib on OS and PFS positions divarasib to supersede first‑generation agents as the preferred KRAS G12C inhibitor in pretreated NSCLC, subject to regulatory review.
- Best‑in‑Class Claim Validated: The pivotal data substantiate Roche/Genentech’s best‑in‑class, next‑generation positioning – greater preclinical potency and selectivity translating into a clinically meaningful survival advantage and nearly double the response rate.
- Biomarker‑Agnostic Benefit: Consistent efficacy regardless of PD‑L1 or KEAP1 status broadens the addressable population and simplifies treatment selection, particularly for KEAP1‑mutated patients who typically respond poorly to existing therapies.
- Franchise Expansion for Roche Group: Divarasib adds a differentiated, orally administered precision‑oncology asset to Roche’s lung cancer portfolio and strengthens its competitive stance in the rapidly evolving KRAS‑targeted therapy landscape.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding divarasib, including regulatory submissions and approvals based on the Krascendo 1 study, commercialization potential, and further clinical development. Divarasib remains investigational and has not been approved by any regulatory authority for any indication; actual results may differ materially due to risks including regulatory review outcomes, competitive therapies, reimbursement and market adoption, and real‑world safety experience.-Fineline Info & Tech
